Get the latest news, insights, and market updates on SKYE (Skye Bioscience, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight
The annual conference presented over 100 scientific sessions featuring innovations from leading pharmaceutical companies, including Novo Nordisk, Eli Lilly and Company, Viking Therapeutics, Ascletis Pharma, Skye Bioscience, Palatin Technologies, Inc., Neurogastrx, Inc., OrsoBio, Metsera, and others, revealing not only significant advances in drug efficacy but also reshaping the multibillion-dollar obesity therapeutics market. These presentations collectively demonstrate that obesity management h Nov 13, 2025 - $SKYE
Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update
Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a clean neuropsychiatric safety profile and no increase in gastrointestinal adverse events.Nimacimab plus semaglutide showed additional reduction in waist circumference of -3.2 cm vs. semaglutide alone.Rebound weight gain was lower in the 12-week post-treatment follow-up period in patients treated wi Nov 10, 2025 - $SKYE
Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025
SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Monday, November 10, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its third quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day. The live webca Nov 5, 2025 - $SKYE
Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
During 12-week post-treatment period, nimacimab plus semaglutide blunts weight regain compared to semaglutide alone in subset analysisSAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will present a late-breaking oral presentation at ObesityWeek 2025 on November 7, 2025, in Atlanta, Georgia. The pr Nov 5, 2025 - $SKYE
Why Skye Bioscience (SKYE) Is Down 51.0% After Releasing Phase 2a Nimacimab Trial Results and What's Next
Skye Bioscience recently held a special call to discuss the topline results from its Phase 2a clinical trial evaluating Nimacimab as both a monotherapy and in combination therapy. This announcement is particularly significant, as topline clinical trial data plays a critical role in shaping the outlook for clinical-stage biopharmaceutical companies. We'll examine how the release of Phase 2a topline data for Nimacimab shapes Skye Bioscience's investment narrative and future prospects. This... Oct 7, 2025 - $SKYE
Top Midday Decliners
Skye Bioscience (SKYE) shares plummeted 60% amid heavy trading intraday after the company said Monda Oct 6, 2025 - $SKYE
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.Clinically meaningful additional weight loss observed with combination of nimacimab, a peripheral CB1 inhibitor, and semaglutide compared to semaglutide alone.Nimacimab alone and in combination demonstrated a clean safety profile, with no added gastrointestinal adverse events and Oct 6, 2025 - $SKYE
Skye shares crash as obesity drug falls short in key study
The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to boost the effects of incretin therapies like Wegovy. Oct 6, 2025 - $SKYE
Could This New Drug Be The Safer Way To Fight Obesity?
On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting. The study demonstrated that nimacimab was safe, well-tolerated, and exhibited predictable pharmacokinetics and low immunogenicity across multiple ascending dose cohorts. There were no serious adverse events, no discontinuations due Sep 19, 2025 - $SKYE
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple